Cargando…

CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance

Delayed diagnosis of ovarian cancer, as well as high recurrence rates and lack of personalized therapy options, are among the causes for poor survival figures. Much effort is made towards developing new therapeutic possibilities, however predictive biomarkers are still unavailable. CCNE1 amplificati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sapoznik, Stav, Aviel-Ronen, Sarit, Bahar-Shany, Keren, Zadok, Oranit, Levanon, Keren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617501/ https://www.ncbi.nlm.nih.gov/pubmed/28977941 http://dx.doi.org/10.18632/oncotarget.19272

Ejemplares similares

Activation-Induced Cytidine Deaminase Links Ovulation-Induced Inflammation and Serous Carcinogenesis
por: Sapoznik, Stav, et al.
Publicado: (2016)

FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis
por: Levanon, Keren, et al.
Publicado: (2013)

Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types
por: Ben-Hamo, Rotem, et al.
Publicado: (2019)

RNA biomarkers from proximal liquid biopsy for diagnosis of ovarian cancer
por: Hulstaert, Eva, et al.
Publicado: (2022)

α-methylacyl-CoA racemase (AMACR) expression in chordomas differentiates them from chondrosarcomas
por: Aviel-Ronen, Sarit, et al.
Publicado: (2016)

CCNE1 amplification among metastatic sites in patients with gynecologic high-grade serous carcinoma
por: Margolis, Benjamin, et al.
Publicado: (2021)

Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53
por: Lindzen, Moshit, et al.
Publicado: (2021)

Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma
por: Chan, Angela MY, et al.
Publicado: (2020)

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
por: Kang, Eun‐Young, et al.
Publicado: (2022)

CCNE1 Amplification and Centrosome Number Abnormality in Serous Tubal Intraepithelial Carcinoma- Further Evidence Supporting its Role as a Precursor of Ovarian High-Grade Serous Carcinoma
por: Kuhn, Elisabetta, et al.
Publicado: (2016)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes
por: Petersen, Shariska, et al.
Publicado: (2020)

Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma
por: Nunes, Mariana, et al.
Publicado: (2022)

Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics
por: Noack, Sabrina, et al.
Publicado: (2018)

Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
por: Matthews, Bayley G., et al.
Publicado: (2021)

The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line
por: Nunes, Mariana, et al.
Publicado: (2022)

Concurrent Primary Peritoneal Low-Grade Serous Carcinoma and Endometrial High-Grade Serous Carcinoma
por: Lockyer, Megan G., et al.
Publicado: (2015)

Ascitic Senescent T Cells Are Linked to Chemoresistance in Patients With Advanced High-Grade Serous Ovarian Cancer
por: Zhang, Jie, et al.
Publicado: (2022)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas
por: NAKAYAMA, KENTARO, et al.
Publicado: (2015)

Identification of Chemoresistance-Associated Key Genes and Pathways in High-Grade Serous Ovarian Cancer by Bioinformatics Analyses
por: Wu, Yong, et al.
Publicado: (2020)

Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer
por: Feng, Li-yuan, et al.
Publicado: (2021)

MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis
por: Zanotti, Laura, et al.
Publicado: (2017)

EMatch: an efficient method for aligning atomic resolution subunits into intermediate-resolution cryo-EM maps of large macromolecular assemblies
por: Dror, Oranit, et al.
Publicado: (2007)

DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers
por: Gull, Nicole, et al.
Publicado: (2022)

Bilateral Serous Psammocarcinoma of Ovary: Rare Variant Low Grade Serous Carcinoma
por: Jena, Saubhagya Kumar, et al.
Publicado: (2015)

Ex Vivo Culture of Primary Human Fallopian Tube Epithelial Cells
por: Fotheringham, Susan, et al.
Publicado: (2011)

The Continuum of Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary
por: Wong, Kwong-Kwok, et al.
Publicado: (2007)

Concomitant diagnosis of endometrial and breast cancer - does the sequence matters?
por: Stern, Tomer, et al.
Publicado: (2021)

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma
por: Norris, Eric J, et al.
Publicado: (2019)

CT features of low grade serous carcinoma of the ovary
por: Pannu, Harpreet K.
Publicado: (2015)

Educational Case: High-Grade Serous Carcinoma of the Ovary
por: Bunde, Sophia, et al.
Publicado: (2021)

Low-Grade Serous Carcinoma of the Ovary: The Current Status
por: Babaier, Abdulaziz, et al.
Publicado: (2022)

Molecular Management of High-Grade Serous Ovarian Carcinoma
por: Punzón-Jiménez, Paula, et al.
Publicado: (2022)

Primary ex-vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis
por: Levanon, Keren, et al.
Publicado: (2009)

Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
por: Ducie, Jennifer, et al.
Publicado: (2017)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
por: Ribeiro e Ribeiro, Renan, et al.
Publicado: (2021)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Trends of low-grade serous ovarian carcinoma in the United States
por: Matsuo, Koji, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mi3t2732ebtidqc10ihbinong1